Correction: POC1A induces epithelial-mesenchymal transition to promote growth and metastasis through the STAT3 signaling pathway in triple-negative breast cancer.

Yuzhou Qian, Yu Che, Shanqi Li, Xue Zhang, Qingshu Li, Yong Zhu, Long Wang, Xuedong Yin

Abstract readPublished Erratum

In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

Erratum for
POC1A induces epithelial-mesenchymal transition to promote growth and metastasis through the STAT3 signaling pathway in triple-negative breast cancer.2025

5 · Who and what money

Authors and funding

8 authors.

Yuzhou Qian *Institute of Life Sciences, Chongqing Medical University, Chongqing, 400016, China.

Yu Che *Institute of Life Sciences, Chongqing Medical University, Chongqing, 400016, China.

Shanqi LiDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Xue ZhangDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Qingshu LiDepartment of Pathology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.

Yong ZhuInstitute of Life Sciences, Chongqing Medical University, Chongqing, 400016, China. yongz59@cqmu.edu.cn.

Long WangDepartment Of Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing, 400030, China. wanglong@cqu.edu.cn.

Xuedong YinDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. yinxuedong@hospital.cqmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41184740

DOI10.1186/s10020-025-01369-1

PMCPMC12584225

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.